FINWIRES · TerminalLIVE
FINWIRES

Cutia Therapeutics公司的局部麻醉剂CU-30101在中国获批

By

-- Cutia Therapeutics(港交所代码:2487)周四在香港交易所发布公告称,其外用麻醉剂CU-30101已在中国获批上市。 该药物为利多卡因和丁卡因乳膏制剂,获批的依据是其三期临床试验结果,该试验表明该产品与参考药物Pliaglis疗效相当。

Related Articles

Asia

ScinoPharm Taiwan Logs NT$16.5 Million Profit in Q1

ScinoPharm Taiwan (TPE:1789) posted a profit attributable to owners of NT$16.5 million, or NT$0.02 per share, in the first quarter of the year, according to a Wednesday Taiwan bourse filing.Shares slid over 2% in Thursday's midday trade.Operating revenue stood at NT$659.7 million, the pharmaceutical company said.The company did not provide comparative year-ago figures.

$TPE:1789
Asia

Kina Securities Lists Papua New Guinea's First Wholesale Corporate Bond

Kina Securities' (ASX:KSL) 235 million Papua New Guinean Kina, 10-year unsecured subordinated wholesale corporate bond was listed on PNGX Markets, the operator of Papua New Guinea's national stock exchange, on Wednesday, according to a Thursday Australian bourse filing.This represents Papua New Guinea's first listed wholesale corporate bond.The firm expects the issuance to support its balance sheet strength, capital management objectives, and the growth of its banking and financial services operations.Its shares rose 1% in recent trading on Thursday.

$ASX:KSL
Asia

Home First Q4 Profit Soars to INR 1.5 Billion, Beats Estimates

Home First Finance Company India's (NSE:HOMEFIRST, BOM:543259) profit after tax rose to 1.49 billion Indian rupees in the fiscal fourth quarter ended March 31, from 1.05 billion rupees a year ago.Earnings per share came in at 14.22 rupees from 11.45 rupees a year ago, the financial services provider said in a filing to the Indian stock exchanges on Wednesday. The EPS was higher than the 14.08 rupees estimated by the analysts polled by Visible Alpha.Total revenue from operations also increased to 5.01 billion rupees from 2.15 billion rupees a year ago.The company's board recommended a dividend of 5.20 rupees per share of a face value of 2 rupees each for the financial year ended March 31.The company's shares were down 2% in recent trade.

$BOM:543259$NSE:HOMEFIRST
Cutia Therapeutics公司的局部麻醉剂CU-30101在中国获批 | FINWIRES